Fetch a single therapeutic candidate + its junction IDs.
Cross-org ids return 404.
Cost: read — rate bucket only.
Bearer authentication header of the form Bearer <token>, where <token> is your auth token.
Successful Response
A therapeutic candidate as returned by /v1.
Carries the junction-table IDs (source antibodies, antigens) and the
initial_variant_id surfaced by create_candidate so a caller
can submit pipelines against it without a second round-trip.
Opaque therapeutic-candidate identifier (UUID).
"c0f5e4b1-a7d2-4e0b-9f8c-1b2d3e4f5a6b"
Project this candidate belongs to.
"7b4a3c0f-2e6d-4c7a-9e8f-1d3b5a2c4e6f"
Short human label shown in dashboards and logs.
Molecular format. Single-arm (mab, nanobody, scfv, fc_fusion) require one H+L pair or a single-chain spec. Multi-arm formats require all arms' chain specs at create time.
mab, nanobody, scfv, fc_fusion, bispecific_kih, bispecific_crossmab, bispecific_common_lc, bite, dart, dvd_ig, tandem_scfv, trispecific_tandem_scfv, trispecific_igg_scfv, trispecific_knh_scfv Therapeutic modality. naked_antibody is the default; adc and radioconjugate require a subsequent ADC-design record before payload synthesis.
naked_antibody, adc, car, radioconjugate, t_cell_engager ISO-8601 timestamp (UTC) when the candidate was registered.
ISO-8601 timestamp (UTC) of the most recent mutation.
Polymorphic discriminator. Always therapeutic_candidate.
"therapeutic_candidate"Free-form metadata bag — the bispecific formats use this for arm assignments; other formats leave it empty.
Optional freeform note shown alongside the candidate.
Source (parental) antibodies linked to this candidate. Maintained via the /v1/therapeutic-candidates/{id}/source-antibodies/{sa_id} endpoints.
Antigens this candidate targets. Maintained via the /v1/therapeutic-candidates/{id}/antigens/{antigen_id} endpoints.
The baseline variant (v1) auto-created alongside this candidate. Populated on create responses; null on read responses — to walk variants post-creation, list them via the variants resource (not yet exposed in /v1, Phase 3 follow-up).